Australia's most trusted
source of pharma news
Tuesday, 11 November 2025
Posted 10 November 2025 PM
In an eleventh-hour change to the PBAC November agenda, Boehringer Ingelheim withdrew its submission for psoriasis drug, Spevigo.
The new listing for the prevention of generalised pustular psoriasis (GPP) flares was scratched from the agenda just 24 hours before the Committee kicked off its three-day meeting which concluded on Friday.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.